Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 20, 2009

Lab21 Acquires Plasmatec Subsidiary from Axis-Shield

  • Lab21 acquired U.K.-based in vitro diagnostics manufacturer and distributor, Plasmatec Laboratory Products, from Axis-Shield.  Plasmatec sells a comprehensive range of diagnostic tests in regions including Europe, Central and South America, Africa, the Middle East, and Asia Pacific.

    “This is a great acquisition for Lab21. Plasmatec is a highly successful business and gives further critical mass to our diagnostic products division. This acquisition follows the purchase earlier this year of Biotec Laboratories and underlines the momentum of our buy-and-build strategy,” explains Graham Mullis, CEO of Lab21.

    Ian Gilham, Axis-Shield CEO, says the company felt Lab21 was better placed to further develop the Plasmatec business model. “This divestment reflects our increasing focus on high margin diagnostic technologies and markets and our investment in state-of-the-art testing at point-of-care.”

     


    ♦♦♦
    Related News

    Lab21 Acquires Biotec Laboratories to Expand Diagnostic Focus (Mar. 3, 2009)



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »